Genedx Holdings Corp (WGS)

$135.80 +4.30 (3.27%)
Market Cap 3.82B
Revenue (ttm) 305.45M
Net Income (ttm) -52.29M
EPS (ttm) N/A
PE Ratio 66.02
Forward PE 224.24
Profit Margin -17.12%
Debt to Equity Ratio 0.18
Volume 233,400
Avg Vol 506,472
Day's Range N/A - N/A
Shares Out 28.91M
Stochastic %K 71%
Beta 2.01
Analysts Strong Sell
Price Target $169.12

Company Profile

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 888 729 1206
Fax: 201 421 2010
Address:
North Tower, 6th Floor 333 Ludlow Street, Stamford, United States
Macarran
Macarran Jan. 6 at 10:43 AM
$WGS The rats abandon ship, https://www.quiverquant.com/stock/WGS/news/
0 · Reply
CatRocks
CatRocks Jan. 5 at 3:35 PM
$WGS Faceplanted into that support level.
0 · Reply
Roberto24
Roberto24 Jan. 2 at 10:34 PM
$WGS Give me 140
0 · Reply
Roberto24
Roberto24 Jan. 2 at 10:34 PM
$WGS
0 · Reply
11thestate
11thestate Jan. 2 at 2:40 PM
$WGS has agreed to settle with investors over claims that it misled them in connection with its 2021 de-SPAC merger and denied a fully informed redemption decision. Who’s eligible? Anyone who purchased $WGS shares between July 19, 2021 and July 22, 2021. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.08 — but if only ~25% of eligible investors file, the effective payout could increase to $0.32. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/cmls-investor-settlement
0 · Reply
CatRocks
CatRocks Dec. 31 at 3:18 PM
$MPTI $WGS $KYTCF / $KITS $NYAX $CTRE $SPY Sending some kudos to the under-the-radar stocks!
0 · Reply
CatRocks
CatRocks Dec. 31 at 2:54 PM
$NYAX Maybe headed to $60 if we get a clean day above this resistance. $CELH $WGS
0 · Reply
BidAskBalance
BidAskBalance Dec. 25 at 4:40 PM
$WGS Macro forces may influence direction, yet internal execution remains the decisive factor. Cash flow visibility will determine how patient investors remain. Momentum becomes sustainable only with dependable execution. Patience is reasonable — but it must be matched by tangible progress.
0 · Reply
CarverX
CarverX Dec. 22 at 4:05 PM
$WGS Bullish chart still intact. 3 month, 6 month etc forming higher lows. Time to fill the 170 gap 🚀🚀🚀
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:04 PM
Canaccord Genuity has updated their rating for GeneDx Holdings ( $WGS ) to Buy with a price target of 170.
0 · Reply
Latest News on WGS
GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

Jan 6, 2026, 8:30 AM EST - 14 hours ago

GeneDx Appoints Dr. Linda Genen as Chief Medical Officer to Accelerate the Future of Genomic-First Care

GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

Jan 5, 2026, 8:30 AM EST - 1 day ago

GeneDx Leads Rare Disease Genomics with Unmatched Research and Clinical Impact in 2025

GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

Dec 30, 2025, 8:00 AM EST - 7 days ago

GeneDx to Present at the J.P. Morgan 2026 Healthcare Conference

JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

Dec 15, 2025, 8:30 AM EST - 22 days ago

JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the Year

Eight stock picks to play one of the healthiest corners of the market

Dec 11, 2025, 10:37 AM EST - 26 days ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND INSM MASI NTRA PODD UNH

HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Nov 30, 2025, 3:20 PM EST - 5 weeks ago

HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

6 Healthcare Stocks With Strong Upward Momentum

Nov 18, 2025, 12:59 PM EST - 7 weeks ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH ELAN GH MEDP

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

Nov 6, 2025, 8:00 AM EST - 2 months ago

GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual Meeting

GeneDx to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 2 months ago

GeneDx to Participate in Upcoming Investor Conferences

GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 3:41 PM EDT - 2 months ago

GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Oct 28, 2025, 6:30 AM EDT - 2 months ago

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth

Oct 27, 2025, 8:00 AM EDT - 2 months ago

GeneDx: A Moment Of Reckoning As Market Awaits Q3 Testing Growth

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Oct 27, 2025, 8:00 AM EDT - 2 months ago

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

Oct 24, 2025, 9:40 AM EDT - 2 months ago

Halper Sadeh LLC Encourages GeneDx Holdings Corp. Shareholders to Contact the Firm to Discuss Their Rights

GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025

Oct 22, 2025, 8:00 AM EDT - 2 months ago

GeneDx Showcases Leadership in Genomic Newborn Screening at ICoNS 2025

GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing

Oct 20, 2025, 8:00 AM EDT - 2 months ago

GeneDx Granted FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ Testing

GeneDX CEO Katherine Stueland on how the company is using AI to save lives

Oct 15, 2025, 3:30 PM EDT - 2 months ago

GeneDX CEO Katherine Stueland on how the company is using AI to save lives

GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company

Oct 15, 2025, 11:45 AM EDT - 2 months ago

GeneDX CEO Katherine Stueland on if the cuts at NIH impact the company

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

Oct 15, 2025, 9:15 AM EDT - 2 months ago

Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot

ILMN

GeneDx's Blueprint For The Next Healthcare Revolution

Oct 15, 2025, 2:55 AM EDT - 2 months ago

GeneDx's Blueprint For The Next Healthcare Revolution

How GeneDX CEO Katherine Stueland is using AI to save lives

Oct 14, 2025, 3:17 PM EDT - 3 months ago

How GeneDX CEO Katherine Stueland is using AI to save lives

GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

Oct 14, 2025, 8:00 AM EDT - 3 months ago

GeneDx Appoints Dr. Mimi Lee as Chief Precision Medicine Officer

GeneDx to Partner with Florida's Sunshine Genetics Network, Launching Nation's First State-Backed Genomic Newborn Screening Program

Oct 13, 2025, 8:00 AM EDT - 3 months ago

GeneDx to Partner with Florida's Sunshine Genetics Network, Launching Nation's First State-Backed Genomic Newborn Screening Program

GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program

Oct 9, 2025, 8:00 AM EDT - 3 months ago

GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program

GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Oct 8, 2025, 8:00 AM EDT - 3 months ago

GeneDx to Showcase Pioneering Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025

Oct 7, 2025, 8:00 AM EDT - 3 months ago

GeneDx to Report Third Quarter 2025 Financial Results on Tuesday, October 28, 2025

GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award

Oct 1, 2025, 4:01 PM EDT - 3 months ago

GeneDx Announces First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award

GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

Sep 30, 2025, 8:00 AM EDT - 3 months ago

GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference

Sep 25, 2025, 8:00 AM EDT - 3 months ago

GeneDx Infinity™ Pioneers a New Era of Genetic Medicine with its Introduction at the American Academy of Pediatrics National Conference

GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors

Sep 18, 2025, 8:00 AM EDT - 3 months ago

GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors

GeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 10:45 AM EDT - 4 months ago

GeneDx Holdings Corp. (WGS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Seer Appoints Isaac Ro to its Board of Directors

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Seer Appoints Isaac Ro to its Board of Directors

SEER

Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS)

Aug 6, 2025, 9:30 AM EDT - 5 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS)

GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth

Jul 31, 2025, 10:22 AM EDT - 5 months ago

GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group

Jul 31, 2025, 3:30 AM EDT - 5 months ago

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Investigation With the DJS Law Group

GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm

Jul 30, 2025, 5:07 PM EDT - 5 months ago

GeneDx Holdings Corp. Investors: Company Investigated by the Portnoy Law Firm

GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options

Jul 30, 2025, 8:38 AM EDT - 5 months ago

GeneDx CEO on rare disease diagnosis: Earlier testing gives families and clinicians more options

GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 5:06 PM EDT - 5 months ago

GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript

GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 29, 2025, 6:30 AM EDT - 5 months ago

GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

Jul 28, 2025, 9:43 AM EDT - 5 months ago

WGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law Firm

GeneDx: Strong Testing Volume And An Invaluable Genomic Database

Jul 15, 2025, 2:52 AM EDT - 6 months ago

GeneDx: Strong Testing Volume And An Invaluable Genomic Database

GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

Jul 10, 2025, 8:30 AM EDT - 6 months ago

GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

Jun 25, 2025, 8:30 AM EDT - 6 months ago

GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability

Jun 23, 2025, 3:17 PM EDT - 7 months ago

GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

May 22, 2025, 8:00 AM EDT - 8 months ago

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

Macarran
Macarran Jan. 6 at 10:43 AM
$WGS The rats abandon ship, https://www.quiverquant.com/stock/WGS/news/
0 · Reply
CatRocks
CatRocks Jan. 5 at 3:35 PM
$WGS Faceplanted into that support level.
0 · Reply
Roberto24
Roberto24 Jan. 2 at 10:34 PM
$WGS Give me 140
0 · Reply
Roberto24
Roberto24 Jan. 2 at 10:34 PM
$WGS
0 · Reply
11thestate
11thestate Jan. 2 at 2:40 PM
$WGS has agreed to settle with investors over claims that it misled them in connection with its 2021 de-SPAC merger and denied a fully informed redemption decision. Who’s eligible? Anyone who purchased $WGS shares between July 19, 2021 and July 22, 2021. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.08 — but if only ~25% of eligible investors file, the effective payout could increase to $0.32. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Typically within 8–12 months after court approval of the settlement. To file your claim: https://11th.com/cases/cmls-investor-settlement
0 · Reply
CatRocks
CatRocks Dec. 31 at 3:18 PM
$MPTI $WGS $KYTCF / $KITS $NYAX $CTRE $SPY Sending some kudos to the under-the-radar stocks!
0 · Reply
CatRocks
CatRocks Dec. 31 at 2:54 PM
$NYAX Maybe headed to $60 if we get a clean day above this resistance. $CELH $WGS
0 · Reply
BidAskBalance
BidAskBalance Dec. 25 at 4:40 PM
$WGS Macro forces may influence direction, yet internal execution remains the decisive factor. Cash flow visibility will determine how patient investors remain. Momentum becomes sustainable only with dependable execution. Patience is reasonable — but it must be matched by tangible progress.
0 · Reply
CarverX
CarverX Dec. 22 at 4:05 PM
$WGS Bullish chart still intact. 3 month, 6 month etc forming higher lows. Time to fill the 170 gap 🚀🚀🚀
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:04 PM
Canaccord Genuity has updated their rating for GeneDx Holdings ( $WGS ) to Buy with a price target of 170.
0 · Reply
Roberto24
Roberto24 Dec. 21 at 6:22 PM
$WGS
0 · Reply
11thestate
11thestate Dec. 19 at 4:31 PM
$WGS is now accepting claims for a 21M settlement it is paying to investors over claims that shareholders were misled in connection with the company’s 2021 de-SPAC merger and denied a fully informed choice about redeeming their shares. Even if you missed the deadline, if you bought $WGS between July 19, 2021 and July 22, 2021, you still can file for payment here: https://11th.com/cases/cmls-investor-settlement
0 · Reply
WAJeff
WAJeff Dec. 18 at 7:45 PM
$WGS Really bad timing adding this at $167.48 on 11/26, should have had a tight stop but didn’t. Took a 19.7% loss, uptrend died the moment I got involved. I’ve made some good trades lately but this and a $SPOT 590s entry were duds.
0 · Reply
CarverX
CarverX Dec. 17 at 8:17 PM
$WGS Jefferies raises target price to $180 from $150 🚀🚀🚀
0 · Reply
CarverX
CarverX Dec. 17 at 3:43 PM
$WGS https://www.reuters.com/business/healthcare-pharmaceuticals/kennedy-approves-adding-two-rare-disorders-newborn-screenings-2025-12-16/
0 · Reply
Mike18181
Mike18181 Dec. 16 at 11:19 PM
$WGS This stock is exciting and companies will invest or even buyout eventually. 200 bucks a share is a reality upcoming as there genomics is superior ! Back up in the next few weeks.
0 · Reply
CarverX
CarverX Dec. 16 at 9:00 PM
$WGS Added shares today! Looking for bounce off of 50 day ema 🚀🚀🚀
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 6:19 PM
Wells Fargo has adjusted their stance on GeneDx Holdings ( $WGS ), setting the rating to Equal-Weight with a target price of 140 → 155.
0 · Reply
DARKP00L
DARKP00L Dec. 15 at 2:24 PM
$WGS 08:55 on Dec. 15 2025 GeneDx's GUARDIAN Study Honored By JAMA For Demonstrating Genomic Newborn Screening Can Detect Serious Childhood Conditions Missed By Traditional Methods #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Dec. 12 at 11:09 AM
BTIG has updated their rating for GeneDx Holdings ( $WGS ) to Buy with a price target of 200.
0 · Reply
Yassine727
Yassine727 Dec. 10 at 3:28 PM
$WGS flagging..
0 · Reply
JesC_Swings
JesC_Swings Dec. 10 at 11:03 AM
I’m monitoring these as call option candidates. $GLW $WGS $MU $LMND $MU want to see some bigger volume and to get above the $260 price. $WGS is forming a nice pendant. Breakout from that and I’m in. $GLW great volume and breakout above the bull flag. I would have opened a position Friday had I seen it. Oh well still pointing to an all time high. Will open a small position today and add to it if we break $92.50 $LMND great pendant setup here looking for a break above $80 to enter.
0 · Reply